Subscribe to VETERINARY PRACTICE NEWS   SUBSCRIBER SERVICES    Bookmark and Share
VPN Logo   
 Home   About Us   Contact Us
1:45 PM   April 19, 2014
Your E-mail:
 

 
Bookmark and Share
Abaxis Launches Quantitative Canine Lyme Disease Test

Posted: Tuesday, Dec. 27, 2011, 4:20 p.m. EST

Abaxis Launches Quantitative Canine Lyme Disease TestAbaxis Inc. added a quantitative antibody test for canine Lyme disease to its line of tests available through the Abaxis Veterinary Reference Laboratories Division in Olathe, Kan., the company reported today.

The test measures a combination of antibodies to peptides which mimic certain antigens of the Borrelia burgdorferi spirochete. The antibodies are not found in vaccinated or noninfected patients, allowing for a definitive diagnosis of the disease, according to Kenneth Aron, Ph.D., Abaxis' chief technology officer.

The test may be used as a standalone diagnostic test to determine infection status or efficacy during treatment. It also may be used as a quantitative confirmation test for Abaxis’ upcoming VetScan Lyme Rapid Test, which is under development, according to the Union City, Calif.-based company.

<HOME>

 Give us your opinion on
Abaxis Launches Quantitative Canine Lyme Disease Test

Submit a Comment

Industry Professional Site: Comments from non-industry professionals will be removed.

Click here to subscribe

Subscriber Services

See all veterinary videos
Featured Vet Grooming Video 
Video Button
Facebook
BROUGHT TO YOU BY Veterinary Practice News

Copyright ©   I-5 Publishing, LLC. All rights reserved.
Our Privacy Policy has changed.
PRIVACY POLICY/YOUR CALIFORNIA PRIVACY RIGHTS.
Terms of Use | Guidelines for Participation

Gold Standard

*Content generated by our loyal visitors, which includes comments and club postings, is free of constraints from our editors’ red pens, and therefore not governed by I-5 Publishing, LLC’s Gold Standard Quality Content, but instead allowed to follow the free form expression necessary for quick, inspired and spontaneous communication.